AN1792

(redirected from Betabloc)

AN1792

A synthetic form of the 42-residue A beta protein seen in Alzheimer’s disease (AD) brains. It prevents appearance of amyloid plaques and the neuropathology characteristic of autosomal dominant AD in young PDAPP mice; immunisation of older mice with established AD-like pathology resulted in a marked reduction or stopped disease progression.
AN-792 made it to early trials as an immune therapy for AD; some patients developed CNS inflammation; trials were halted in 2002.
References in periodicals archive ?
The 78-year-old suffers from glaucoma, heart disease and diabetes - and every day he takes three glucopage, two lynoxin, 75ml of betabloc, 20ml of Nexium, warfarin, lanoxin and aspirin.
Food and Drug Administration ("FDA") and the commencement of Phase I safety trials with Betabloc (AN 1792), our new therapeutic agent intended for the treatment of Alzheimer's disease.
16 /PRNewswire/ -- Elan Corporation, plc (NYSE: ELN) ("Elan") today announced that it has initiated Phase I clinical studies with Betabloc (AN 1792), its new therapeutic agent intended for the treatment of Alzheimer's disease ("AD").
The study, which will include up to 48 patients, will evaluate several dose levels of Betabloc and is expected to take one year to complete.